You've got to love it when a big pharmaceutical company wants to make both patients and your pocketbook healthier. Sure, Eli Lilly (NYSE: LLY) has five drugs in its arsenal that each topped the $1 billion mark in sales last year. However, Lilly also shares the wealth, yielding a hefty 2.9% dividend.

Yes, many of the Big Pharma names have generous payouts. Really.

The chunky distributions are definitely nice, but is the sector -- Lilly in particular -- ready to provide healthy capital appreciation too? That's what this week's Duel is all about.

Ryan Fuhrmann is our bull this week. Brian Lawler counters as our bear. Is this Income Investor recommendation the remedy for what ails you? Read on and decide for yourself.

Duel on!

• Read the bull argument
• Read the bear argument
• Read the bullish rebuttal
• Read the bearish rebuttal
• Sound off in Motley Fool CAPS
• Vote for the winner

Eli Lilly, Johnson & Johnson, and GlaxoSmithKline are all Income Investor recommendations. See if your best prescription is a steady diet of high-yielding stocks for the next 30 days through a free trial subscription offer.

Pfizer is an Inside Value pick.

Longtime Fool contributor Rick Munarriz does not own shares in any of the companies in this story. The Fool has a disclosure policy.